CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Human Genome Sciences says a recent study showed its experimental hepatitis C drug is well-tolerated and reduces the virus in some treatment-naive patients. The study involved 56 patients who were each given one of five doses of Albuferon. Patients were given two doses of Albuferon 14 days apart and were followed for six weeks, with the rate of viral load assessed on the 28th day. Sixty-nine percent of the patients taking the two highest doses achieved the targeted viral load reduction on the 28th day of the study. Hepatitis C is the most common chronic blood-borne infection in the developed world and afflicts about 4 million people in the United States, the company said. (AP)
From our Sponsors
Most Popular
Watch Now: Pride Today
Latest Stories
After trans people, Trump now erases bisexual people from Stonewall National Monument
July 10 2025 10:45 PM
Black trans woman Dream Johnson killed in Washington, D.C.
July 10 2025 7:59 PM
5 lesbian power couples who play for the same sports team
July 10 2025 12:13 PM
'Gay progressive hot daddy' blasts 'bozos' using his pics for right-wing memes
July 10 2025 11:59 AM